Claims for Patent: 10,182,969

Summary for Patent: 10,182,969

Title:	Aseptic piercing system and method
Abstract:	The present disclosure provides aseptic vial piercing and sterilization systems, and methods of assembling, using and sterilizing same. The systems and methods utilize a pre-sterilized primary container including a first end, a first cavity, a second end with an opening in communication with the first cavity, a septum at least partially sealing the opening, and a product within the first cavity. The systems and methods include an injection assembly including a first end portion of a hollow flowpath forming member. The injection assembly and the primary container may be assembled in a non-sterile environment to form a second cavity extending about the first end portion of the flowpath forming member and to the primary container. The second cavity may then be selectively sterilized in a non-deleterious manner to the product to allow the first end portion to aseptically pierce the septum to extend into the first cavity.
Inventor(s):	Rachel Paige Arnott, Bart E. BURGESS, Michael Cupicha, Alexei Goraltchouk, Bryan Grygus, Mike Stelmah
Assignee:	Regeneron Pharmaceuticals Inc
Application Number:	US15/066,791

Details for Patent 10,182,969

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011		2036-03-10
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	August 16, 2018		2036-03-10
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355	August 18, 2023		2036-03-10

International Patent Family for US Patent 10,182,969

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016145206
United States of America	2022401302
United States of America	2019105230
United States of America	2016262984